You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameLosartan
Accession NumberDB00678  (APRD00052)
TypeSmall Molecule
GroupsApproved
Description

Losartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. Losartan and its longer acting metabolite, E-3174, lower blood pressure by antagonizing the renin-angiotensin-aldosterone system (RAAS); they compete with angiotensin II for binding to the type-1 angiotensin II receptor (AT1) subtype and prevents the blood pressure increasing effects of angiotensin II. Unlike angiotensin-converting enzyme (ACE) inhibitors, ARBs do not have the adverse effect of dry cough. Losartan may be used to treat hypertension, isolated systolic hypertension, left ventricular hypertrophy and diabetic nephropathy. It may also be used as an alternative agent for the treatment of systolic dysfunction, myocardial infarction, coronary artery disease, and heart failure.

Structure
Thumb
Synonyms
(2-Butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazol-5-yl)methanol
2-N-Butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole
DuP 89
Losartan
External Identifiers
  • MK594
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act Losartantablet100 mgoralActavis Pharma Company2012-01-25Not applicableCanada
Act Losartantablet50 mgoralActavis Pharma Company2012-01-25Not applicableCanada
Act Losartantablet25 mgoralActavis Pharma Company2012-01-25Not applicableCanada
Ag-losartantablet100 mgoralAngita Pharma Inc.Not applicableNot applicableCanada
Ag-losartantablet50 mgoralAngita Pharma Inc.Not applicableNot applicableCanada
Ag-losartantablet25 mgoralAngita Pharma Inc.Not applicableNot applicableCanada
Auro-losartantablet100.0 mgoralAuro Pharma Inc2013-03-26Not applicableCanada
Auro-losartantablet50.0 mgoralAuro Pharma Inc2013-03-26Not applicableCanada
Auro-losartantablet25.0 mgoralAuro Pharma Inc2013-03-26Not applicableCanada
Bio-losartantablet100 mgoralBiomed Pharma2016-06-08Not applicableCanada
Bio-losartantablet50 mgoralBiomed Pharma2016-05-09Not applicableCanada
Bio-losartantablet25 mgoralBiomed Pharma2016-05-09Not applicableCanada
Cozaartablet, film coated50 mg/1oralCardinal Health1995-04-14Not applicableUs
Cozaartablet, film coated25 mg/1oralMerck Sharp & Dohme Corp.1995-04-14Not applicableUs
Cozaartablet, film coated50 mg/1oralbryant ranch prepack1995-04-14Not applicableUs
Cozaartablet25 mg/1oralREMEDYREPACK INC.2011-04-07Not applicableUs
Cozaartablet, film coated25 mg/1oralCardinal Health1995-04-14Not applicableUs
Cozaartablet, film coated25 mg/1oralPhysicians Total Care, Inc.2004-06-02Not applicableUs
Cozaartablet100 mgoralMerck Canada Inc1998-01-16Not applicableCanada
Cozaartablet, film coated50 mg/1oralPhysicians Total Care, Inc.1996-04-01Not applicableUs
Cozaartablet50 mgoralMerck Canada Inc1995-12-31Not applicableCanada
Cozaartablet, film coated100 mg/1oralPhysicians Total Care, Inc.2003-08-06Not applicableUs
Cozaartablet, film coated100 mg/1oralMerck Sharp & Dohme Corp.1995-04-14Not applicableUs
Cozaartablet25 mgoralMerck Canada Inc1995-12-31Not applicableCanada
Cozaartablet, film coated25 mg/1oralREMEDYREPACK INC.2011-05-19Not applicableUs
Cozaartablet, film coated100 mg/1oralPd Rx Pharmaceuticals, Inc.1995-04-14Not applicableUs
Cozaartablet, film coated50 mg/1oralMerck Sharp & Dohme Corp.1995-04-14Not applicableUs
Cozaartablet, film coated100 mg/1oralbryant ranch prepack1995-04-14Not applicableUs
Cozaartablet, film coated100 mg/1oralREMEDYREPACK INC.2011-04-22Not applicableUs
Ipg-losartantablet50 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-losartantablet25 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-losartantablet100 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Jamp-losartantablet25 mgoralJamp Pharma Corporation2013-06-11Not applicableCanada
Jamp-losartantablet100 mgoralJamp Pharma Corporation2013-06-11Not applicableCanada
Jamp-losartantablet50 mgoralJamp Pharma Corporation2013-06-11Not applicableCanada
Losartantablet100 mgoralFrosst A Division Of Merck Canada IncNot applicableNot applicableCanada
Losartantablet50 mgoralSivem Pharmaceuticals Ulc2012-07-05Not applicableCanada
Losartantablet100 mgoralSanis Health Inc2012-07-20Not applicableCanada
Losartantablet100 mgoralPro Doc Limitee2012-11-22Not applicableCanada
Losartantablet50 mgoralFrosst A Division Of Merck Canada IncNot applicableNot applicableCanada
Losartantablet50 mgoralSanis Health Inc2012-07-20Not applicableCanada
Losartantablet50 mgoralPro Doc Limitee2012-11-22Not applicableCanada
Losartantablet25 mgoralFrosst A Division Of Merck Canada IncNot applicableNot applicableCanada
Losartantablet25 mgoralSanis Health Inc2012-07-20Not applicableCanada
Losartantablet25 mgoralPro Doc Limitee2012-11-22Not applicableCanada
Losartantablet100 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Losartantablet100 mgoralActavis Pharma CompanyNot applicableNot applicableCanada
Losartantablet50 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Losartantablet50 mgoralActavis Pharma CompanyNot applicableNot applicableCanada
Losartantablet25 mgoralSivem Pharmaceuticals Ulc2012-07-05Not applicableCanada
Losartantablet100 mgoralSivem Pharmaceuticals Ulc2012-07-05Not applicableCanada
Losartantablet25 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Losartantablet25 mgoralActavis Pharma CompanyNot applicableNot applicableCanada
Losartan Potassiumtablet25 mgoralJubilant Generics LimitedNot applicableNot applicableCanada
Losartan Potassiumtablet, film coated100 mg/1oralSandoz Inc.1995-04-14Not applicableUs
Losartan Potassiumtablet25 mgoralJubilant Generics LimitedNot applicableNot applicableCanada
Losartan Potassiumtablet, film coated50 mg/1oralSandoz Inc.1995-04-14Not applicableUs
Losartan Potassiumtablet100 mgoralJubilant Generics LimitedNot applicableNot applicableCanada
Losartan Potassiumtablet, film coated25 mg/1oralSandoz Inc.1995-04-14Not applicableUs
Losartan Potassiumtablet100 mgoralJubilant Generics LimitedNot applicableNot applicableCanada
Losartan Potassiumtablet50 mgoralJubilant Generics LimitedNot applicableNot applicableCanada
Losartan Potassiumtablet50 mgoralJubilant Generics LimitedNot applicableNot applicableCanada
Mar-losartantablet100 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mar-losartantablet50 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mar-losartantablet25 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mint-losartantablet25.0 mgoralMint Pharmaceuticals Inc2014-01-16Not applicableCanada
Mint-losartantablet100.0 mgoralMint Pharmaceuticals Inc2014-01-16Not applicableCanada
Mint-losartantablet50.0 mgoralMint Pharmaceuticals Inc2014-01-16Not applicableCanada
Mylan-losartantablet25 mgoralMylan Pharmaceuticals Ulc2012-01-25Not applicableCanada
Mylan-losartantablet100 mgoralMylan Pharmaceuticals Ulc2012-01-25Not applicableCanada
Mylan-losartantablet50 mgoralMylan Pharmaceuticals Ulc2012-01-25Not applicableCanada
PMS-losartantablet50 mgoralPharmascience Inc2012-01-25Not applicableCanada
PMS-losartantablet25 mgoralPharmascience Inc2012-01-25Not applicableCanada
PMS-losartantablet100 mgoralPharmascience Inc2012-01-25Not applicableCanada
Priva-losartantablet25 mgoralPharmapar Inc2016-05-25Not applicableCanada
Priva-losartantablet100 mgoralPharmapar Inc2016-05-25Not applicableCanada
Priva-losartantablet50 mgoralPharmapar Inc2016-05-09Not applicableCanada
Ran-losartantablet100 mgoralRanbaxy Pharmaceuticals Canada Inc.2013-06-11Not applicableCanada
Ran-losartantablet50 mgoralRanbaxy Pharmaceuticals Canada Inc.2013-06-11Not applicableCanada
Ran-losartantablet25 mgoralRanbaxy Pharmaceuticals Canada Inc.2013-06-11Not applicableCanada
Sandoz Losartantablet100 mgoralSandoz Canada Incorporated2012-01-25Not applicableCanada
Sandoz Losartantablet50 mgoralSandoz Canada Incorporated2012-01-25Not applicableCanada
Sandoz Losartantablet25 mgoralSandoz Canada Incorporated2012-01-25Not applicableCanada
Septa-losartantablet100 mgoralSepta Pharmaceuticals Inc2014-07-03Not applicableCanada
Septa-losartantablet50 mgoralSepta Pharmaceuticals Inc2014-07-03Not applicableCanada
Septa-losartantablet25 mgoralSepta Pharmaceuticals Inc2014-07-03Not applicableCanada
Teva-losartantablet50 mgoralTeva Canada Limited2012-01-25Not applicableCanada
Teva-losartantablet25 mgoralTeva Canada Limited2012-02-28Not applicableCanada
Teva-losartantablet100 mgoralTeva Canada Limited2012-01-25Not applicableCanada
Van-losartantablet25 mgoralVanc Pharmaceuticals Inc2015-06-08Not applicableCanada
Van-losartantablet100 mgoralVanc Pharmaceuticals Inc2015-06-08Not applicableCanada
Van-losartantablet50 mgoralVanc Pharmaceuticals Inc2015-06-08Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-losartantablet25 mgoralApotex Inc2012-04-13Not applicableCanada
Apo-losartantablet100 mgoralApotex Inc2012-01-25Not applicableCanada
Apo-losartantablet50 mgoralApotex Inc2012-01-25Not applicableCanada
Losartantablet, film coated100 mg/1oralVirtus Pharmaceuticals2015-07-14Not applicableUs
Losartantablet, film coated50 mg/1oralVirtus Pharmaceuticals2015-07-14Not applicableUs
Losartantablet, film coated25 mg/1oralVirtus Pharmaceuticals2015-07-14Not applicableUs
Losartan Potassiumtablet100 mg/1oralSTAT Rx USA LLC2010-10-06Not applicableUs
Losartan Potassiumtablet, film coated100 mg/1oralMacleods Pharmaceuticals Limited2012-06-01Not applicableUs
Losartan Potassiumtablet, film coated25 mg/1oralQualitest Pharmaceuticals2012-01-04Not applicableUs
Losartan Potassiumtablet, film coated100 mg/1oralMedsource Pharmaceuticals2010-04-06Not applicableUs
Losartan Potassiumtablet50 mg/1oralClinical Solutions Wholesale2010-10-06Not applicableUs
Losartan Potassiumtablet, film coated100 mg/1oralEndo Pharmaceuticals Inc. DBA Endo Generic Products2010-11-12Not applicableUs
Losartan Potassiumtablet, film coated100 mg/1oralMc Kesson Packaging Services2010-10-04Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralLegacy Pharmaceutical Packaging, Llc2010-04-06Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralMc Kesson Contract Packaging2013-04-10Not applicableUs
Losartan Potassiumtablet, film coated100 mg/1oralKAISER FOUNDATION HOSPITALS2016-03-16Not applicableUs
Losartan Potassiumtablet, film coated100 mg/1oralClinical Solutions Wholesale2010-04-06Not applicableUs
Losartan Potassiumtablet50 mg/1oralDIRECT RX2015-01-01Not applicableUs
Losartan Potassiumtablet, film coated100 mg/1oralReady Meds2012-01-04Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralCarilion Materials Management2010-04-06Not applicableUs
Losartan Potassiumtablet, film coated100 mg/1oralLegacy Pharmaceutical Packaging, Llc2010-04-06Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralVirtus Pharmaceuticals LLC2014-03-25Not applicableUs
Losartan Potassiumtablet, film coated100 mg/1oralQualitest Pharmaceuticals2012-01-04Not applicableUs
Losartan Potassiumtablet25 mg/1oralRoxane Laboratories, Inc.2010-10-06Not applicableUs
Losartan Potassiumtablet25 mg/1oralREMEDYREPACK INC.2011-12-07Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralApotex Corp2010-10-03Not applicableUs
Losartan Potassiumtablet, film coated25 mg/1oralProficient Rx LP2010-04-06Not applicableUs
Losartan Potassiumtablet, film coated100 mg/1oralAurobindo Pharma Limited2010-10-06Not applicableUs
Losartan Potassiumtablet100 mg/1oralLupin Pharmaceuticals, Inc.2015-12-02Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralPreferred Pharmaceuticals, Inc.2013-01-25Not applicableUs
Losartan Potassiumtablet, film coated25 mg/1oralSandoz Inc2010-10-06Not applicableUs
Losartan Potassiumtablet25 mg/1oralMajor Pharmaceuticals2014-06-09Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralCamber Pharmaceuticals, Inc.2015-08-19Not applicableUs
Losartan Potassiumtablet, film coated25 mg/1oralKAISER FOUNDATION HOSPITALS2015-12-01Not applicableUs
Losartan Potassiumtablet, film coated100 mg/1oralMicro Labs Limited2012-12-06Not applicableUs
Losartan Potassiumtablet50 mg/1oralUnit Dose Services2010-10-06Not applicableUs
Losartan Potassiumtablet, film coated100 mg/1oralPhysicians Total Care, Inc.2010-04-13Not applicableUs
Losartan Potassiumtablet, film coated100 mg/1oralRising Pharmaceuticals, Inc2014-07-30Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralMacleods Pharmaceuticals Limited2012-06-01Not applicableUs
Losartan Potassiumtablet, film coated100 mg/1oralWatson Laboratories, Inc.2011-02-22Not applicableUs
Losartan Potassiumtablet50 mg/1oralREMEDYREPACK INC.2013-05-15Not applicableUs
Losartan Potassiumtablet100 mg/1oralClinical Solutions Wholesale2010-10-06Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralEndo Pharmaceuticals Inc. DBA Endo Generic Products2010-11-12Not applicableUs
Losartan Potassiumtablet, film coated100 mg/1oralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2010-10-03Not applicableUs
Losartan Potassiumtablet50 mg/1oralLegacy Pharmaceutical Packaging2011-02-21Not applicableUs
Losartan Potassiumtablet50 mg/1oralLife Line Home Care Services, Inc.2010-10-06Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralKAISER FOUNDATION HOSPITALS2016-03-16Not applicableUs
Losartan Potassiumtablet50 mg/1oralMajor Pharmaceuticals2014-06-09Not applicableUs
Losartan Potassiumtablet, film coated25 mg/1oralCamber Pharmaceuticals, Inc.2015-08-19Not applicableUs
Losartan Potassiumtablet, film coated100 mg/1oralTeva Pharmaceuticals USA Inc2010-04-06Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralMicro Labs Limited2012-12-06Not applicableUs
Losartan Potassiumtablet25 mg/1oralUnit Dose Services2010-10-06Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralPhysicians Total Care, Inc.2010-04-13Not applicableUs
Losartan Potassiumtablet, film coated25 mg/1oralApotex Corp2010-10-03Not applicableUs
Losartan Potassiumtablet, film coated25 mg/1oralProficient Rx LP2012-01-04Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralAurobindo Pharma Limited2010-10-06Not applicableUs
Losartan Potassiumtablet50 mg/1oralLupin Pharmaceuticals, Inc.2015-12-02Not applicableUs
Losartan Potassiumtablet, film coated100 mg/1oralPreferred Pharmaceuticals, Inc.2013-01-25Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralRising Pharmaceuticals, Inc2014-07-30Not applicableUs
Losartan Potassiumtablet, film coated25 mg/1oralMacleods Pharmaceuticals Limited2012-05-10Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralWatson Laboratories, Inc.2011-02-22Not applicableUs
Losartan Potassiumtablet, film coated100 mg/1oralSolco Healthcare US, LLC2014-07-30Not applicableUs
Losartan Potassiumtablet100 mg/1oralREMEDYREPACK INC.2013-05-14Not applicableUs
Losartan Potassiumtablet, film coated25 mg/1oralEndo Pharmaceuticals Inc. DBA Endo Generic Products2010-11-12Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2010-10-03Not applicableUs
Losartan Potassiumtablet, film coated25 mg/1oralLegacy Pharmaceutical Packaging, Llc2010-04-06Not applicableUs
Losartan Potassiumtablet, film coated25 mg/1oralAvera Mc Kennan Hospital2015-03-09Not applicableUs
Losartan Potassiumtablet100 mg/1oralMajor Pharmaceuticals2014-06-09Not applicableUs
Losartan Potassiumtablet100 mg/1oralUnichem Pharmaceuticals (USA), Inc.2016-01-01Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralTeva Pharmaceuticals USA Inc2010-04-06Not applicableUs
Losartan Potassiumtablet, film coated25 mg/1oralMicro Labs Limited2012-12-06Not applicableUs
Losartan Potassiumtablet100 mg/1oralAv Pak2014-03-27Not applicableUs
Losartan Potassiumtablet, film coated100 mg/1oralGolden State Medical Supply, Inc.2011-02-22Not applicableUs
Losartan Potassiumtablet, film coated25 mg/1oralAurobindo Pharma Limited2010-10-06Not applicableUs
Losartan Potassiumtablet25 mg/1oralLupin Pharmaceuticals, Inc.2015-12-02Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralPreferred Pharmaceuticals, Inc.2011-03-21Not applicableUs
Losartan Potassiumtablet, film coated25 mg/1oralRising Pharmaceuticals, Inc2011-06-01Not applicableUs
Losartan Potassiumtablet, film coated25 mg/1oralWatson Laboratories, Inc.2011-02-22Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralSolco Healthcare US, LLC2014-07-30Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralCardinal Health2011-08-12Not applicableUs
Losartan Potassiumtablet25 mg/1oralSt Marys Medical Park Pharmacy2014-04-21Not applicableUs
Losartan Potassiumtablet, film coated25 mg/1oralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2010-10-03Not applicableUs
Losartan Potassiumtablet, film coated25 mg/1oralDispensing Solutions, Inc.2010-12-28Not applicableUs
Losartan Potassiumtablet25 mg/1oralLegacy Pharmaceutical Packaging2010-10-06Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralPd Rx Pharmaceuticals, Inc.2010-10-06Not applicableUs
Losartan Potassiumtablet, film coated25 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-04-06Not applicableUs
Losartan Potassiumtablet50 mg/1oralUnichem Pharmaceuticals (USA), Inc.2016-01-01Not applicableUs
Losartan Potassiumtablet, film coated25 mg/1oralTeva Pharmaceuticals USA Inc2010-04-06Not applicableUs
Losartan Potassiumtablet25 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-10-06Not applicableUs
Losartan Potassiumtablet50 mg/1oralAv Pak2014-03-27Not applicableUs
Losartan Potassiumtablet50 mg/1oralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralGolden State Medical Supply, Inc.2011-02-22Not applicableUs
Losartan Potassiumtablet, film coated100 mg/1oralCadila Healthcare Limited2010-10-04Not applicableUs
Losartan Potassiumtablet100 mg/1oralLupin Pharmaceuticals, Inc.2010-10-06Not applicableUs
Losartan Potassiumtablet50 mg/1oralPreferred Pharmaceuticals, Inc.2013-06-06Not applicableUs
Losartan Potassiumtablet, film coated100 mg/1oralMylan Pharmaceuticals Inc.2012-12-06Not applicableUs
Losartan Potassiumtablet, film coated25 mg/1oralSolco Healthcare US, LLC2011-06-01Not applicableUs
Losartan Potassiumtablet, film coated100 mg/1oralREMEDYREPACK INC.2012-12-27Not applicableUs
Losartan Potassiumtablet100 mg/1oralSt Marys Medical Park Pharmacy2013-07-11Not applicableUs
Losartan Potassiumtablet, film coated25 mg/1oralbryant ranch prepack2010-10-03Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralDispensing Solutions, Inc.2010-12-28Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralREMEDYREPACK INC.2015-09-17Not applicableUs
Losartan Potassiumtablet50 mg/1oralTorrent Pharmaceuticals Limited2010-10-06Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-04-06Not applicableUs
Losartan Potassiumtablet25 mg/1oralUnichem Pharmaceuticals (USA), Inc.2016-01-01Not applicableUs
Losartan Potassiumtablet100 mg/1oralRoxane Laboratories, Inc.2010-10-06Not applicableUs
Losartan Potassiumtablet50 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-10-06Not applicableUs
Losartan Potassiumtablet25 mg/1oralAv Pak2014-03-27Not applicableUs
Losartan Potassiumtablet100 mg/1oralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Losartan Potassiumtablet, film coated25 mg/1oralGolden State Medical Supply, Inc.2011-02-22Not applicableUs
Losartan Potassiumtablet100 mg/1oralDIRECT RX2014-01-01Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralCadila Healthcare Limited2010-10-04Not applicableUs
Losartan Potassiumtablet50 mg/1oralLupin Pharmaceuticals, Inc.2010-10-06Not applicableUs
Losartan Potassiumtablet50 mg/1oralLegacy Pharmaceutical Packaging, Llc2010-10-06Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralAvera Mc Kennan Hospital2015-03-11Not applicableUs
Losartan Potassiumtablet50 mg/1oralSt Marys Medical Park Pharmacy2013-07-11Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralMed Vantx, Inc.2010-12-28Not applicableUs
Losartan Potassiumtablet, film coated100 mg/1oralAvera Mc Kennan Hospital2015-03-01Not applicableUs
Losartan Potassiumtablet, film coated100 mg/1oralSandoz Inc2010-10-06Not applicableUs
Losartan Potassiumtablet100 mg/1oralTorrent Pharmaceuticals Limited2010-10-06Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralMylan Pharmaceuticals Inc.2012-12-06Not applicableUs
Losartan Potassiumtablet, film coated100 mg/1oralPd Rx Pharmaceuticals, Inc.2010-10-06Not applicableUs
Losartan Potassiumtablet50 mg/1oralREMEDYREPACK INC.2013-02-26Not applicableUs
Losartan Potassiumtablet100 mg/1oralREMEDYREPACK INC.2015-03-07Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralReady Meds2012-01-04Not applicableUs
Losartan Potassiumtablet25 mg/1oralCarilion Materials Management2010-10-06Not applicableUs
Losartan Potassiumtablet100 mg/1oralLegacy Pharmaceutical Packaging2010-10-06Not applicableUs
Losartan Potassiumtablet, film coated25 mg/1oralVirtus Pharmaceuticals LLC2014-03-25Not applicableUs
Losartan Potassiumtablet, film coated25 mg/1oralPd Rx Pharmaceuticals, Inc.2010-10-06Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralQualitest Pharmaceuticals2012-01-04Not applicableUs
Losartan Potassiumtablet25 mg/1oralREMEDYREPACK INC.2011-07-15Not applicableUs
Losartan Potassiumtablet25 mg/1oralREMEDYREPACK INC.2014-04-09Not applicableUs
Losartan Potassiumtablet25 mg/1oralClinical Solutions Wholesale2010-10-06Not applicableUs
Losartan Potassiumtablet25 mg/1oralDIRECT RX2015-12-03Not applicableUs
Losartan Potassiumtablet, film coated25 mg/1oralCadila Healthcare Limited2010-10-04Not applicableUs
Losartan Potassiumtablet25 mg/1oralLupin Pharmaceuticals, Inc.2010-10-06Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralLegacy Pharmaceutical Packaging2010-10-03Not applicableUs
Losartan Potassiumtablet, film coated100 mg/1oralVirtus Pharmaceuticals LLC2014-03-25Not applicableUs
Losartan Potassiumtablet, film coated100 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-04-06Not applicableUs
Losartan Potassiumtablet50 mg/1oralRoxane Laboratories, Inc.2010-10-06Not applicableUs
Losartan Potassiumtablet100 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-10-06Not applicableUs
Losartan Potassiumtablet50 mg/1oralREMEDYREPACK INC.2013-03-08Not applicableUs
Losartan Potassiumtablet, film coated25 mg/1oralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
Losartan Potassiumtablet, film coated100 mg/1oralApotex Corp2010-10-03Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralMed Vantx, Inc.2010-10-03Not applicableUs
Losartan Potassiumtablet100 mg/1oralPreferred Pharmaceuticals, Inc.2015-05-07Not applicableUs
Losartan Potassiumtablet, film coated50 mg/1oralSandoz Inc2010-10-06Not applicableUs
Losartan Potassiumtablet25 mg/1oralTorrent Pharmaceuticals Limited2010-10-06Not applicableUs
Losartan Potassiumtablet, film coated100 mg/1oralCamber Pharmaceuticals, Inc.2015-08-19Not applicableUs
Losartan Potassiumtablet, film coated25 mg/1oralMylan Pharmaceuticals Inc.2012-12-06Not applicableUs
Losartan Potassiumtablet100 mg/1oralUnit Dose Services2010-10-06Not applicableUs
Losartan Potassiumtablet, film coated25 mg/1oralPhysicians Total Care, Inc.2010-04-27Not applicableUs
Losartan Potassium Tablets, 100 mgtablet100 mg/1oralJubilant Cadista Pharmaceuticals Inc.2012-09-18Not applicableUs
Losartan Potassium Tablets, 25 mgtablet25 mg/1oralJubilant Cadista Pharmaceuticals Inc.2012-09-18Not applicableUs
Losartan Potassium Tablets, 50 mgtablet50 mg/1oralJubilant Cadista Pharmaceuticals Inc.2012-09-18Not applicableUs
Losartan Potatssiumtablet50 mg/1oralNew Horizon Rx Group, LLC2013-08-25Not applicableUs
Losortan Potassiumtablet, film coated25 mg/1oralREMEDYREPACK INC.2014-04-01Not applicableUs
Losortan Potassiumtablet, film coated100 mg/1oralAmerican Health Packaging2013-06-13Not applicableUs
Losortan Potassiumtablet, film coated100 mg/1oralRebel Distributors Corp2010-10-04Not applicableUs
Losortan Potassiumtablet, film coated50 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-10-14Not applicableUs
Losortan Potassiumtablet, film coated50 mg/1oralMedsource Pharmaceuticals2010-10-04Not applicableUs
Losortan Potassiumtablet, film coated50 mg/1oralAmerican Health Packaging2013-06-13Not applicableUs
Losortan Potassiumtablet, film coated100 mg/1oralCardinal Health2013-06-13Not applicableUs
Losortan Potassiumtablet, film coated25 mg/1oralAmerican Health Packaging2013-06-13Not applicableUs
Losortan Potassiumtablet, film coated50 mg/1oralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs
Losortan Potassiumtablet, film coated100 mg/1oralProficient Rx LP2010-10-04Not applicableUs
Losortan Potassiumtablet, film coated25 mg/1oralAidarex Pharmaceuticals LLC2010-10-04Not applicableUs
Losortan Potassiumtablet, film coated50 mg/1oralREMEDYREPACK INC.2013-06-03Not applicableUs
Losortan Potassiumtablet, film coated50 mg/1oralProficient Rx LP2010-10-04Not applicableUs
Losortan Potassiumtablet, film coated100 mg/1oralAidarex Pharmaceuticals LLC2010-10-04Not applicableUs
Losortan Potassiumtablet, film coated25 mg/1oralCardinal Health2010-10-14Not applicableUs
Losortan Potassiumtablet, film coated100 mg/1oralZydus Pharmaceuticals (USA) Inc.2010-10-04Not applicableUs
Losortan Potassiumtablet, film coated100 mg/1oralbryant ranch prepack2010-10-04Not applicableUs
Losortan Potassiumtablet, film coated50 mg/1oralZydus Pharmaceuticals (USA) Inc.2010-10-04Not applicableUs
Losortan Potassiumtablet, film coated50 mg/1oralAidarex Pharmaceuticals LLC2010-10-04Not applicableUs
Losortan Potassiumtablet, film coated50 mg/1oralCardinal Health2010-10-14Not applicableUs
Losortan Potassiumtablet, film coated50 mg/1oralRebel Distributors Corp2010-10-04Not applicableUs
Losortan Potassiumtablet, film coated100 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-10-14Not applicableUs
Losortan Potassiumtablet, film coated25 mg/1oralRebel Distributors Corp2010-10-04Not applicableUs
Losortan Potassiumtablet, film coated50 mg/1oralbryant ranch prepack2010-10-04Not applicableUs
Losortan Potassiumtablet, film coated25 mg/1oralZydus Pharmaceuticals (USA) Inc.2010-10-04Not applicableUs
Losortan Potassiumtablet, film coated100 mg/1oralPd Rx Pharmaceuticals, Inc.2010-10-04Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
LortaanNot Available
Brand mixtures
NameLabellerIngredients
Act Losartan/hctActavis Pharma Company
Apo-losartan/hctzApotex Inc
Auro-losartan HctAuro Pharma Inc
HyzaarMerck Sharp & Dohme Corp.
Hyzaar 50/12.5mgMerck Canada Inc
Hyzaar DS 100/25 mgMerck Canada Inc
Jamp-losartan HctzJamp Pharma Corporation
Losartan Potassium and HydrochlorothiazideRoxane Laboratories, Inc.
Losartan-hctzPro Doc Limitee
Losartan/hctSivem Pharmaceuticals Ulc
Losartan/hctzSanis Health Inc
Mint-losartan/hctzMint Pharmaceuticals Inc
Mint-losartan/hctz DSMint Pharmaceuticals Inc
Mylan-losartan HctzMylan Pharmaceuticals Ulc
PMS-losartan-hctzPharmascience Inc
Ratio-losartan HctzTeva Canada Limited
Sandoz Losartan HctSandoz Canada Incorporated
Sandoz Losartan Hct DSSandoz Canada Incorporated
Septa-losartan HctzSepta Pharmaceuticals Inc
Teva-losartan/hctzTeva Canada Limited
Van-losartan-hctzVanc Pharmaceuticals Inc
Salts
Name/CASStructureProperties
Losartan Potassium
Thumb
  • InChI Key: OXCMYAYHXIHQOA-UHFFFAOYSA-N
  • Monoisotopic Mass: 460.118068924
  • Average Mass: 461.001
DBSALT000112
Categories
UNIIJMS50MPO89
CAS number114798-26-4
WeightAverage: 422.911
Monoisotopic: 422.162187095
Chemical FormulaC22H23ClN6O
InChI KeyInChIKey=PSIFNNKUMBGKDQ-UHFFFAOYSA-N
InChI
InChI=1S/C22H23ClN6O/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22/h4-7,9-12,30H,2-3,8,13-14H2,1H3,(H,25,26,27,28)
IUPAC Name
[2-butyl-4-chloro-1-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1H-imidazol-5-yl]methanol
SMILES
CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as biphenyltetrazoles and derivatives. These are organic compounds containing a biphenyl attached to a tetrazole. A carbon atom of the biphenyl moiety is boned to a carbon or the nitrogen atom of the tetrazole moiety.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassAzoles
Sub ClassTetrazoles
Direct ParentBiphenyltetrazoles and derivatives
Alternative Parents
Substituents
  • Biphenyltetrazole
  • Biphenyl
  • 1,2,4,5-tetrasubstituted imidazole
  • Phenylmethylamine
  • Benzenoid
  • N-substituted imidazole
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl chloride
  • Heteroaromatic compound
  • Imidazole
  • Azacycle
  • Hydrocarbon derivative
  • Aromatic alcohol
  • Primary alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Alcohol
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationMay be used as a first line agent to treat uncomplicated hypertension, isolated systolic hypertension and left ventricular hypertrophy. May be used as a first line agent to delay progression of diabetic nephropathy. Losartan may be also used as a second line agent in the treatment of congestive heart failure, systolic dysfunction, myocardial infarction and coronary artery disease in those intolerant of ACE inhibitors.
PharmacodynamicsLosartan is the first of a class of antihypertensive agents called angiotensin II receptor blockers (ARBs). Losartan and its longer acting active metabolite, E-3174, are specific and selective type-1 angiotensin II receptor (AT1) antagonists which block the blood pressure increasing effects angiotensin II via the renin-angiotensin-aldosterone system (RAAS). RAAS is a homeostatic mechanism for regulating hemodynamics, water and electrolyte balance. During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from granular cells of the juxtaglomerular apparatus in the kidneys. Renin cleaves circulating angiotensinogen to angiotensin I, which is cleaved by angiotensin converting enzyme (ACE) to angiotensin II. Angiotensin II increases blood pressure by increasing total peripheral resistance, increasing sodium and water reabsorption in the kidneys via aldosterone secretion, and altering cardiovascular structure. Angiotensin II binds to two receptors: AT1 and type-2 angiotensin II receptor (AT2). AT1 is a G-protein coupled receptor (GPCR) that mediates the vasoconstrictive and aldosterone-secreting effects of angiotensin II. Studies performed in recent years suggest that AT2 antagonizes AT1-mediated effects and directly affects long-term blood pressure control by inducing vasorelaxation and increasing urinary sodium excretion. Angiotensin receptor blockers (ARBs) are non-peptide competitive inhibitors of AT1. ARBs block the ability of angiotensin II to stimulate pressor and cell proliferative effects. Unlike ACE inhibitors, ARBs do not affect bradykinin-induced vasodilation. The overall effect of ARBs is a decrease in blood pressure.
Mechanism of actionLosartan competitively inhibits the binding of angiotensin II to AT1 in many tissues including vascular smooth muscle and the adrenal glands. Losartan is metabolized to its active metabolite, E-3174, which is 10 to 40 times more potent than losartan and acts as a non-competitive AT1 antagonist. Inhibition of angiotensin II binding to AT1 inhibits its AT1-mediated vasoconstrictive and aldosterone-secreting effects and results in decreased vascular resistance and blood pressure. Losartan is 1,000 times more selective for AT1 than AT2. Inhibition of aldosterone secretion may increase sodium and water excretion while decreasing potassium excretion. Losartan is effective for reducing blood pressure and may be used to treat essential hypertension, left ventricular hypertrophy and diabetic nephropathy.
Related Articles
AbsorptionLosartan is well absorbed and undergoes substantial first-pass metabolism; the systemic bioavailability of losartan is approximately 33%. Mean peak concentrations of losartan and its active metabolite are reached in 1 hour and in 3-4 hours, respectively. While maximum plasma concentrations of losartan and its active metabolite are approximately equal, the AUC of the metabolite is about 4 times as great as that of losartan. When given with a meal, absorption is slows down and Cmax decreases.
Volume of distribution
  • 34 L [losartan, healthy subjects]
  • 12 L [active metabolite, healthy subjects]
Protein binding99.7% protein bound, primarily to albumin
Metabolism

Hepatic. Losartan is metabolized to a 5-carboxylic acid derivative (E-3174) via an aldehyde intermediate (E-3179) primarily by cytochrome P450 (CYP) 2C9 and CYP3A4. E-3174 is an active metabolite with 10- to 40-fold higher potency than its parent compound, losartan. Approxiamtely 14% of losartan is converted to E-3174; however, the AUC of E-3174 was found to be 4- to 8-fold higher than losartan and E-3174 is considered the main contributor to the pharmacologic effects of this medication.

SubstrateEnzymesProduct
Losartan
E-3179Details
Losartan
Losartan N2-glucuronideDetails
E-3179
E-3174Details
Route of eliminationFollowing oral administration of losartan, 35% of the dose is recovered in the urine and about 60% in the feces. Following an intravenous dose, 45% is recovered in the urine and 50% in the feces.
Half lifeThe terminal t1/2 of losartan is 2 hours. The active metabolite has a half-life of 6-9 hours.
Clearance
  • Total plasma clearance = 600 mL/min [losartan]
  • Total plasma clearance = 50 mL/min [active metabolite]
  • Renal clearance = 75 mL/min [losartan]
  • Renal clearance = 25 mL/min [active metabolite]
ToxicityHypotension and tachycardia; Bradycardia could occur from parasympathetic (vagal) stimulation, LD50= 1000 mg/kg (orally in rat)
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Losartan Action PathwayDrug actionSMP00162
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier-0.7812
Caco-2 permeable-0.8957
P-glycoprotein substrateSubstrate0.6993
P-glycoprotein inhibitor INon-inhibitor0.8782
P-glycoprotein inhibitor IIInhibitor0.5309
Renal organic cation transporterNon-inhibitor0.5689
CYP450 2C9 substrateNon-substrate0.6839
CYP450 2D6 substrateNon-substrate0.9115
CYP450 3A4 substrateNon-substrate0.6226
CYP450 1A2 substrateInhibitor0.5514
CYP450 2C9 inhibitorNon-inhibitor0.5423
CYP450 2D6 inhibitorNon-inhibitor0.8102
CYP450 2C19 inhibitorInhibitor0.6288
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7049
Ames testNon AMES toxic0.5382
CarcinogenicityNon-carcinogens0.6595
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6055 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.5781
hERG inhibition (predictor II)Inhibitor0.8084
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Merck research laboratories div merck co inc
  • Teva pharmaceuticals usa inc
  • Merck & Co., Inc.
Packagers
Dosage forms
FormRouteStrength
Tabletoral100.0 mg
Tabletoral25.0 mg
Tabletoral50.0 mg
Tabletoral100 mg
Tabletoral25 mg
Tabletoral50 mg
Tablet, film coatedoral100 mg/1
Tablet, film coatedoral25 mg/1
Tablet, film coatedoral50 mg/1
Tablet, film coatedoral
Tabletoral100 mg/1
Tabletoral25 mg/1
Tabletoral50 mg/1
Tabletoral
Prices
Unit descriptionCostUnit
Losartan Potassium 90 50 mg tablet Bottle211.78USD bottle
Losartan Potassium-HCTZ 30 50-12.5 mg tablet Bottle78.05USD bottle
Hyzaar 100-25 mg tablet3.91USD tablet
Hyzaar 100-12.5 mg tablet3.87USD tablet
Hyzaar 100-12.5 tablet3.61USD tablet
Hyzaar 100-25 tablet3.61USD tablet
Losartan Potassium-HCTZ 100-12.5 mg tablet3.54USD tablet
Losartan Potassium-HCTZ 100-25 mg tablet3.54USD tablet
Cozaar 100 mg tablet3.41USD tablet
Losartan potassium 100 mg tablet3.14USD tablet
Hyzaar 50-12.5 mg tablet2.97USD tablet
Hyzaar 50-12.5 tablet2.65USD tablet
Cozaar 50 mg tablet2.5USD tablet
Losartan potassium 50 mg tablet2.26USD tablet
Cozaar 25 mg tablet1.92USD tablet
Losartan potassium 25 mg tablet1.72USD tablet
Cozaar 100 mg Tablet1.31USD tablet
Cozaar 25 mg Tablet1.31USD tablet
Cozaar 50 mg Tablet1.31USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1334092 No1995-01-242012-01-24Canada
CA2085584 No2003-02-112011-06-07Canada
US5210079 No1993-11-112010-11-11Us
US5608075 No1992-03-042009-03-04Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point184 °CPhysProp
water solubility0.82 mg/LNot Available
logP6.1Not Available
pKa5.5MERCK INDEX (1996); approx.
Predicted Properties
PropertyValueSource
Water Solubility0.0047 mg/mLALOGPS
logP4.5ALOGPS
logP5.08ChemAxon
logS-5ALOGPS
pKa (Strongest Acidic)7.4ChemAxon
pKa (Strongest Basic)4.12ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area92.51 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity131.85 m3·mol-1ChemAxon
Polarizability44.86 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Gordon C. Campbell, Jr., Anil M. Dwivedi, Dorothy A. Levorse, James A. McCauley, Krishnaswamy S. Raghavan, “Polymorphs of losartan and the process for the preparation of form II of losartan.” U.S. Patent US5608075, issued May, 1994.

US5608075
General References
  1. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002 Mar 23;359(9311):995-1003. [PubMed:11937178 ]
  2. Guo ZX, Qiu MC: [Losartan downregulates the expression of transforming growth factor beta type I and type II receptors in kidney of diabetic rat]. Zhonghua Nei Ke Za Zhi. 2003 Jun;42(6):403-8. [PubMed:12895325 ]
  3. Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, Cooper TK, Myers L, Klein EC, Liu G, Calvi C, Podowski M, Neptune ER, Halushka MK, Bedja D, Gabrielson K, Rifkin DB, Carta L, Ramirez F, Huso DL, Dietz HC: Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science. 2006 Apr 7;312(5770):117-21. [PubMed:16601194 ]
  4. Sica DA, Gehr TW, Ghosh S: Clinical pharmacokinetics of losartan. Clin Pharmacokinet. 2005;44(8):797-814. [PubMed:16029066 ]
  5. Stanfield, Cindy L.;Germann, William J. (2009). Principles of Human Physiology (3rd ed.). Benjamin-Cummings Publishing Company. [ISBN:978-0321556660 ]
  6. Bader, M. (2004). Renin-angiotensin-aldosterone system. In Encyclopedic reference of molecular pharmacology (pp. 810-814). Berlin: Springer. [ISBN:9783540298328 ]
External Links
ATC CodesC09DA01C09DB06C09CA01
AHFS Codes
  • 24:32.08
PDB EntriesNot Available
FDA labelDownload (212 KB)
MSDSDownload (19 KB)
Interactions
Drug Interactions
Drug
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Losartan.
AlfuzosinAlfuzosin may increase the hypotensive activities of Losartan.
AliskirenAliskiren may increase the hyperkalemic activities of Losartan.
AmifostineLosartan may increase the hypotensive activities of Amifostine.
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Losartan.
ArdeparinArdeparin may increase the hyperkalemic activities of Losartan.
BexaroteneThe serum concentration of Losartan can be decreased when it is combined with Bexarotene.
BosentanThe serum concentration of Losartan can be decreased when it is combined with Bosentan.
BrimonidineBrimonidine may increase the antihypertensive activities of Losartan.
ButabarbitalButabarbital may increase the hypotensive activities of Losartan.
ButethalButethal may increase the hypotensive activities of Losartan.
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Losartan.
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Losartan.
CeritinibThe serum concentration of Losartan can be increased when it is combined with Ceritinib.
CiprofloxacinLosartan may increase the arrhythmogenic activities of Ciprofloxacin.
CyclosporineLosartan may increase the hyperkalemic activities of Cyclosporine.
DabrafenibThe serum concentration of Losartan can be decreased when it is combined with Dabrafenib.
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Losartan.
DeferasiroxThe serum concentration of Losartan can be decreased when it is combined with Deferasirox.
DiazoxideDiazoxide may increase the hypotensive activities of Losartan.
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Losartan.
DrospirenoneLosartan may increase the hyperkalemic activities of Drospirenone.
DuloxetineLosartan may increase the orthostatic hypotensive activities of Duloxetine.
EplerenoneEplerenone may increase the hyperkalemic activities of Losartan.
FloxuridineThe metabolism of Losartan can be decreased when combined with Floxuridine.
FluconazoleThe serum concentration of Losartan can be decreased when it is combined with Fluconazole.
HeparinHeparin may increase the hyperkalemic activities of Losartan.
HeptabarbitalHeptabarbital may increase the hypotensive activities of Losartan.
HexobarbitalHexobarbital may increase the hypotensive activities of Losartan.
InfliximabThe risk or severity of adverse effects can be increased when Losartan is combined with Infliximab.
ItraconazoleThe metabolism of Losartan can be decreased when combined with Itraconazole.
KetoconazoleThe metabolism of Losartan can be decreased when combined with Ketoconazole.
LevodopaLosartan may increase the orthostatic hypotensive activities of Levodopa.
LithiumThe serum concentration of Lithium can be increased when it is combined with Losartan.
MethohexitalMethohexital may increase the hypotensive activities of Losartan.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Losartan.
MifepristoneThe serum concentration of Losartan can be increased when it is combined with Mifepristone.
MitotaneThe serum concentration of Losartan can be decreased when it is combined with Mitotane.
MolsidomineMolsidomine may increase the hypotensive activities of Losartan.
MoxonidineMoxonidine may increase the hypotensive activities of Losartan.
NicorandilNicorandil may increase the hypotensive activities of Losartan.
ObinutuzumabLosartan may increase the hypotensive activities of Obinutuzumab.
PentobarbitalPentobarbital may increase the hypotensive activities of Losartan.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Losartan.
PerindoprilThe risk or severity of adverse effects can be increased when Losartan is combined with Perindopril.
PhenelzinePhenelzine may increase the orthostatic hypotensive activities of Losartan.
PhenytoinThe metabolism of Losartan can be increased when combined with Phenytoin.
PosaconazoleThe metabolism of Losartan can be decreased when combined with Posaconazole.
PrimidonePrimidone may increase the hypotensive activities of Losartan.
QuinineQuinine may increase the hypotensive activities of Losartan.
RifampicinThe serum concentration of Losartan can be decreased when it is combined with Rifampicin.
RisperidoneLosartan may increase the hypotensive activities of Risperidone.
RituximabLosartan may increase the hypotensive activities of Rituximab.
SecobarbitalSecobarbital may increase the hypotensive activities of Losartan.
SildenafilThe metabolism of Sildenafil can be decreased when combined with Losartan.
SiltuximabThe serum concentration of Losartan can be decreased when it is combined with Siltuximab.
St. John's WortThe serum concentration of Losartan can be decreased when it is combined with St. John's Wort.
SulfisoxazoleThe metabolism of Losartan can be decreased when combined with Sulfisoxazole.
TadalafilTadalafil may increase the antihypertensive activities of Losartan.
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Losartan.
TocilizumabThe serum concentration of Losartan can be decreased when it is combined with Tocilizumab.
TolvaptanTolvaptan may increase the hyperkalemic activities of Losartan.
TorasemideThe metabolism of Torasemide can be decreased when combined with Losartan.
TranylcypromineTranylcypromine may increase the orthostatic hypotensive activities of Losartan.
TreprostinilTreprostinil may increase the hypotensive activities of Losartan.
TriamtereneLosartan may increase the hyperkalemic activities of Triamterene.
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Losartan.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Losartan.
VardenafilVardenafil may increase the antihypertensive activities of Losartan.
VoriconazoleThe metabolism of Losartan can be decreased when combined with Voriconazole.
YohimbineYohimbine may decrease the antihypertensive activities of Losartan.
Food Interactions
  • Take without regard to meals. Take at same time each day. Food delays absorption, but does not affect the extent of absorption.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
Receptor for angiotensin II. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.
Gene Name:
AGTR1
Uniprot ID:
P30556
Molecular Weight:
41060.53 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Sardo MA, Castaldo M, Cinquegrani M, Bonaiuto M, Fontana L, Campo S, Campo GM, Altavilla D, Saitta A: Effects of AT1 receptor antagonist losartan on sICAM-1 and TNF-alpha levels in uncomplicated hypertensive patients. Angiology. 2004 Mar-Apr;55(2):195-203. [PubMed:15026875 ]
  3. Dickstein K, Timmermans P, Segal R: Losartan: a selective angiotensin II type 1 (AT1) receptor antagonist for the treatment of heart failure. Expert Opin Investig Drugs. 1998 Nov;7(11):1897-914. [PubMed:15991937 ]
  4. Anand-Srivastava MB, Palaparti A: Angiotensin-II-induced enhanced expression of Gi proteins is attenuated by losartan in A10 vascular smooth muscle cells: role of AT1 receptors. Can J Physiol Pharmacol. 2003 Feb;81(2):150-8. [PubMed:12710529 ]
  5. Rocha I, Bras-Rosario L, Amparo-Barros M, Silva-Carvalho L: Angiotensin AT1 receptor antagonist losartan and the defence reaction in the anaesthetised rat. Effect on the carotid chemoreflex. Exp Physiol. 2003 May;88(3):309-14. [PubMed:12719755 ]
  6. Guan J, Cheng DY, Chen XJ, Zhang Y, Wang H, Su QL: [The effects of losartan on pulmonary arterial collagen and AT1 in chronic hypoxic rats]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2004 Nov;35(6):774-7. [PubMed:15573751 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Song JC, White CM: Pharmacologic, pharmacokinetic, and therapeutic differences among angiotensin II receptor antagonists. Pharmacotherapy. 2000 Feb;20(2):130-9. [PubMed:10678291 ]
  2. Sica DA, Gehr TW, Ghosh S: Clinical pharmacokinetics of losartan. Clin Pharmacokinet. 2005;44(8):797-814. [PubMed:16029066 ]
  3. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  5. Yasar U, Forslund-Bergengren C, Tybring G, Dorado P, Llerena A, Sjoqvist F, Eliasson E, Dahl ML: Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clin Pharmacol Ther. 2002 Jan;71(1):89-98. [PubMed:11823761 ]
  6. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Song JC, White CM: Pharmacologic, pharmacokinetic, and therapeutic differences among angiotensin II receptor antagonists. Pharmacotherapy. 2000 Feb;20(2):130-9. [PubMed:10678291 ]
  2. Sica DA, Gehr TW, Ghosh S: Clinical pharmacokinetics of losartan. Clin Pharmacokinet. 2005;44(8):797-814. [PubMed:16029066 ]
  3. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the IX-alpha-C8 and IX-alpha-C12 monoconjugates and diconjugate. Is also able to catalyze the glucuronidation of 17beta-estradiol, 17alpha-ethinylestradiol, 1-hydroxypyrene, 4-methylumbelliferone, 1-naph...
Gene Name:
UGT1A1
Uniprot ID:
P22309
Molecular Weight:
59590.91 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Retinoic acid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A3
Uniprot ID:
P35503
Molecular Weight:
60337.835 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Protein kinase c binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A10
Uniprot ID:
Q9HAW8
Molecular Weight:
59809.075 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Glucuronosyltransferase activity
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol suggests it may play an important role in regulating the level and activity of these potent and active estrogen metabolites. Is also active with androsterone, hyodeoxycholic acid and tetrachlorocatechol...
Gene Name:
UGT2B7
Uniprot ID:
P16662
Molecular Weight:
60694.12 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Glucuronosyltransferase activity
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. The major substrates of this isozyme are eugenol > 4-methylumbelliferone > dihydrotestosterone (DHT) > androstane-3-alpha,17-beta-diol (3-alpha-diol) > testosterone > androsterone (ADT).
Gene Name:
UGT2B17
Uniprot ID:
O75795
Molecular Weight:
61094.915 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Takara K, Kakumoto M, Tanigawara Y, Funakoshi J, Sakaeda T, Okumura K: Interaction of digoxin with antihypertensive drugs via MDR1. Life Sci. 2002 Feb 15;70(13):1491-500. [PubMed:11895100 ]
  2. Borgnia MJ, Eytan GD, Assaraf YG: Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity. J Biol Chem. 1996 Feb 9;271(6):3163-71. [PubMed:8621716 ]
  3. Soldner A, Benet LZ, Mutschler E, Christians U: Active transport of the angiotensin-II antagonist losartan and its main metabolite EXP 3174 across MDCK-MDR1 and caco-2 cell monolayers. Br J Pharmacol. 2000 Mar;129(6):1235-43. [PubMed:10725273 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-in...
Gene Name:
SLC22A6
Uniprot ID:
Q4U2R8
Molecular Weight:
61815.78 Da
References
  1. Race JE, Grassl SM, Williams WJ, Holtzman EJ: Molecular cloning and characterization of two novel human renal organic anion transporters (hOAT1 and hOAT3). Biochem Biophys Res Commun. 1999 Feb 16;255(2):508-14. [PubMed:10049739 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Urate transmembrane transporter activity
Specific Function:
Required for efficient urate re-absorption in the kidney. Regulates blood urate levels. Mediates saturable urate uptake by facilitating the exchange of urate against organic anions.
Gene Name:
SLC22A12
Uniprot ID:
Q96S37
Molecular Weight:
59629.57 Da
References
  1. Lipkowitz MS: Regulation of uric acid excretion by the kidney. Curr Rheumatol Rep. 2012 Apr;14(2):179-88. doi: 10.1007/s11926-012-0240-z. [PubMed:22359229 ]
  2. Burnier M, Roch-Ramel F, Brunner HR: Renal effects of angiotensin II receptor blockade in normotensive subjects. Kidney Int. 1996 Jun;49(6):1787-90. [PubMed:8743498 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sugar:proton symporter activity
Specific Function:
Transport urate and fructose. May have a role in the urate reabsorption by proximal tubules. Also transports glucose at low rate.
Gene Name:
SLC2A9
Uniprot ID:
Q9NRM0
Molecular Weight:
58701.205 Da
References
  1. Lipkowitz MS: Regulation of uric acid excretion by the kidney. Curr Rheumatol Rep. 2012 Apr;14(2):179-88. doi: 10.1007/s11926-012-0240-z. [PubMed:22359229 ]
  2. Burnier M, Roch-Ramel F, Brunner HR: Renal effects of angiotensin II receptor blockade in normotensive subjects. Kidney Int. 1996 Jun;49(6):1787-90. [PubMed:8743498 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23